Author

I. Yurgelonis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Gribenko· 1 shared A. S. Anderson· 1 shared B. Kreiswirth· 1 shared D. K. Rai· 1 shared E. Titova· 1 shared H. A. Rothan· 1 shared K. M. White· 1 shared L. Hao· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Gribenko

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MicrobiologybioRxivJan 17, 2022

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

D. K. Rai, I. Yurgelonis, P. McMonagle…·R. D. Cardin

This paper evaluates the antiviral activity of Nirmatrelvir against multiple SARS-CoV-2 variants using qRT-PCR in VeroE6 cells, showing potent inhibition across all tested variants.

DOI 10.1016/j.antiviral.2026.106517

experimental assaydrug response / drug discovery

𝕏 PostBluesky